文献速递浆细胞疾病

铜-64标记达雷妥尤单抗作为多发性骨髓瘤PET/CT显像示踪剂

Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma.
PubMed 文献 · Blood · 2018-01-04

研究将靶向CD38的人源抗体达雷妥尤单抗与DOTA螯合剂偶联并用正电子核素铜-64标记,制备64Cu-DOTA-Dara。在骨髓瘤小鼠模型中,该探针可高效结合骨髓瘤细胞表面CD38,主要富集于与肿瘤相关的骨骼;其PET/CT检测骨髓瘤细胞播散的分辨率和特异性高于18F-FDG PET/CT,且敏感性高于生物发光信号。

要点

  • 64Cu-DOTA-Dara可高效结合骨髓瘤细胞表面CD38。
  • 小鼠模型中64Cu-DOTA-Dara主要富集于与肿瘤相关的骨骼。
  • 64Cu-DOTA-Dara PET/CT检测播散的分辨率和特异性高于18F-FDG PET/CT。

核心结论

  • 作者认为已有支持证据表明64Cu-DOTA-Dara可作为多发性骨髓瘤的新型显像剂。

研究设计与样本

  • 研究为临床前小鼠模型研究,将达雷妥尤单抗与DOTA螯合剂偶联并用铜-64标记为64Cu-DOTA-Dara。

主要发现

  • 64Cu-DOTA-Dara能高效结合骨髓瘤细胞表面CD38,在小鼠模型中主要于与肿瘤相关的骨骼中被检测到。
  • 64Cu-DOTA-Dara PET/CT检测骨髓瘤细胞播散的分辨率和特异性高于18F-FDG PET/CT。
  • 64Cu-DOTA-Dara PET/CT检测骨髓瘤细胞播散的敏感性高于生物发光信号。

关键数值与推荐

  • 64Cu-DOTA-Dara为达雷妥尤单抗经DOTA螯合后标记铜-64所得。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As a growing number of patients with multiple myeloma (MM) respond to upfront therapies while eventually relapsing in a time frame that is often unpredictable, attention has increasingly focused on developing novel diagnostic criteria to also account for disease dissemination. Positron emission tomography/computed tomography (PET/CT) is often used as a noninvasive monitoring strategy to assess cancer cell dissemination, but because the uptake of the currently used radiotracer 18fluorodeoxyglucose (18F-FDG) is a function of the metabolic activity of both malignant and nonmalignant cells, the results frequently lack sufficient specificity. Radiolabeled antibodies targeting MM tissue may detect disease irrespective of cell metabolism. Hence, we conjugated the clinically significant CD38-directed human antibody daratumumab (Darzalex [Dara]) to the DOTA chelator and labeled it with the positron-emitting radionuclide copper 64 (64Cu; 64Cu-DOTA-Dara). Here, we show that 64Cu-DOTA-Dara can efficiently bind CD38 on the surface of MM cells and was mainly detected in the bones associated with tumor in a MM murine model. We also show that PET/CT based on 64Cu-DOTA-Dara displays a higher resolution and specificity to detect MM cell dissemination than does 18F-FDG PET/CT and was even more sensitive than were bioluminescence signals. We therefore have supporting evidence for using 64Cu-DOTA-Dara as a novel imaging agent for MM.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Caserta E, Chea J, Minnix M, et al. Copper 64-labeled daratumumab as a PET/CT imaging tracer for multiple myeloma. Blood. 2018. PMID: 29301755. doi:10.1182/blood-2017-09-807263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。